Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

September 13, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration...

2 days ago New Drug Approvals

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

6 days ago New Drug Approvals

FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13...

6 days ago New Drug Approvals

Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI

CAMBRIDGE, Mass., Sept. 18, 2024. Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results...

today Clinical Trials

SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM

For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson...

today News for Health Professionals

Greater Adherence to MIND Diet Linked to Reduced Cognitive Impairment

Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet adherence is associated with a reduced...

today News for Health Professionals

FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis

The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe...

today News for Health Professionals

Trends in Prehospital Encounters for Youth Opioid Overdose Identified

Prehospital encounters for youth opioid overdoses increased before the COVID-19 pandemic, then increased with onset, and then stabilized, according to...

today News for Health Professionals

Long-Term Outcomes Good for Face Transplant Recipients, Study Finds

There have been 50 face transplants performed in 11 countries since the surgery was pioneered back in 2005, and long-term outcomes have been favorable,...

today Medical

Buildup of Metals in Body Can Worsen Heart Disease

Cadmium, uranium, cobalt: These and other metals found in the environment can collect in the body and exacerbate heart disease, new research suggests. "Our...

today Medical

FDA Expands Use of Breast Cancer Drug Kisqali

Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's...

today Medical

Feeling Content Helps Shield You From Heart Attack, Stroke

Folks who are content with what they’ve got could be less likely to suffer a heart attack or stroke, a new study suggests. “Our findings support...

yesterday Medical

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30

HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical...

yesterday Clinical Trials

Why Beans Are a Natural Superfood

Beans may sometimes give you gas, but one expert says that shouldn't stop you from finding ways to include them in your diet. Why? Because they are packed...

4 days ago Medical

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If...

6 days ago FDA Alerts

Recently Added

Recently added consumer and prescribing information: Pavblu, Livdelzi, Yorvipath, Crexont, Lymphir, Epysqli, Pyzchiva, Ahzantive, Ohtuvayre, Sofdra

For Consumers

For Professionals

For Researchers

Pharmaceutical Company Directory

Latest FDA New Drug Approvals

Ocrevus Zunovo Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) is a CD20-directed cytolytic antibody and hyaluronidase combination used for the...
Ebglyss Ebglyss (lebrikizumab-lbkz) is a targeted IL-13 inhibitor used for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults...
Pavblu Pavblu (aflibercept-ayyh) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Eylea indicated for the treatment of...

More FDA approvals

Drugs in Development (Not yet approved)

Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...

More drugs in development

Drug Information

Tools

News & Alerts

Professionals

Top 100 Drugs

Recommended Content

Find Drugs & Conditions

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

FDA Expands Use of Breast Cancer Drug Kisqali

Recently Added

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

Drugs in Development (Not yet approved)

Drug Information

Tools

News & Alerts

Professionals

Top 100 Drugs